Study Title: Enhancement of Statin Effects on Lipid Lowering and Reduction of Cardiovascular Risk Score by (−)-Epicatechin in Proof-of-Concept Pilot Study
Citation: Taub et al., 2025. Clinical and Translational Science
What the Study Found: This pilot study looked at adding (−)-epicatechin to statin therapy. The combination improved lipid-related markers and reduced cardiovascular risk scores more than statins alone, suggesting a complementary effect on cardiometabolic pathways.
What this means in real life: This study suggests that supporting cellular energy pathways may enhance how the body responds to standard cardiovascular treatments like statins. It highlights that lipid control and heart health are not just about cholesterol levels, but also about how efficiently cells manage energy and stress.
Contenu associé
- Want to understand how cellular energy connects to cardiovascular risk factors like cholesterol, blood pressure, and metabolic health? → 4 Risk Factors for Heart Disease and How to Improve Them Through a Better Understanding of Cellular Energy
- Curious how mitochondrial dysfunction shows up in real metabolic conditions like lipid imbalance and fat accumulation? → Mitochondrial Health and Fatty Liver